Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-234 manufacturers

Filters

Filters

Filters , active

Country of origin : Australia
1 products found

pp-234

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
Australia
GMP approvals
TGA
Comments
Indication: Neuroendocrine Tumors (NETs) / Clinical stage: Phase 3 (registrational trial, recruitment 2026) / Modality: Biologic - radiopharmaceutical (copper-64 labeled SARTATE) / Mechanism & Target: Somatostatin receptor imaging/therapy / Route & form: IV injection / Differentiation: Copper-based radiopharmaceutical with improved imaging vs standard 68Ga-DOTATATE
Manufacturer #39440

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.